BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30927977)

  • 1. Therapy-associated leukemic transformation in myeloproliferative neoplasms - What do we know?
    Cuthbert D; Stein BL
    Best Pract Res Clin Haematol; 2019 Mar; 32(1):65-73. PubMed ID: 30927977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preface.
    Michaelis LC
    Best Pract Res Clin Haematol; 2019 Mar; 32(1):1-2. PubMed ID: 30927968
    [No Abstract]   [Full Text] [Related]  

  • 3. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
    Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
    Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
    [No Abstract]   [Full Text] [Related]  

  • 4. Myeloid malignancies after treatment for solid tumours.
    Guru Murthy GS; Abedin S
    Best Pract Res Clin Haematol; 2019 Mar; 32(1):40-46. PubMed ID: 30927974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focus on the epigenome in the myeloproliferative neoplasms.
    Kim E; Abdel-Wahab O
    Hematology Am Soc Hematol Educ Program; 2013; 2013():538-44. PubMed ID: 24319229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms.
    Hong J; Lee JH; Byun JM; Lee JY; Koh Y; Shin DY; Lee JO; Hwang SM; Choi HS; Kim I; Yoon SS; Bang SM
    Blood Adv; 2019 Nov; 3(22):3700-3708. PubMed ID: 31765478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
    Björkholm M; Hultcrantz M; Derolf ÅR
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):141-53. PubMed ID: 25189725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms.
    O'Sullivan JM; Harrison CN
    Mol Cell Endocrinol; 2017 Aug; 451():71-79. PubMed ID: 28167129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic options for leukemic transformation in patients with myeloproliferative neoplasms.
    Khan M; Siddiqi R; Gangat N
    Leuk Res; 2017 Dec; 63():78-84. PubMed ID: 29121538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.
    Zhang SJ; Rampal R; Manshouri T; Patel J; Mensah N; Kayserian A; Hricik T; Heguy A; Hedvat C; Gönen M; Kantarjian H; Levine RL; Abdel-Wahab O; Verstovsek S
    Blood; 2012 May; 119(19):4480-5. PubMed ID: 22431577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.
    Rampal R; Ahn J; Abdel-Wahab O; Nahas M; Wang K; Lipson D; Otto GA; Yelensky R; Hricik T; McKenney AS; Chiosis G; Chung YR; Pandey S; van den Brink MR; Armstrong SA; Dogan A; Intlekofer A; Manshouri T; Park CY; Verstovsek S; Rapaport F; Stephens PJ; Miller VA; Levine RL
    Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5401-10. PubMed ID: 25516983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
    Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
    Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.
    Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S124-9. PubMed ID: 27521308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Burkitt leukemia with precursor B-cell features that developed after ruxolitinib treatment in a patient with hydroxyurea-refractory JAK2
    Fukutsuka K; Iioka F; Maekawa F; Nakagawa M; Kishimori C; Hayashida M; Tagawa S; Akasaka T; Honjo G; Ohno H
    J Clin Exp Hematop; 2021 Jun; 61(2):114-119. PubMed ID: 33994432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
    Nazha A; Gerds AT
    Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase.
    Cherington C; Slack JL; Leis J; Adams RH; Reeder CB; Mikhael JR; Camoriano J; Noel P; Fauble V; Betcher J; Higgins MS; Gillette-Kent G; Tremblay LD; Peterson ME; Olsen JJ; Tibes R; Mesa RA
    Leuk Res; 2012 Sep; 36(9):1147-51. PubMed ID: 22578777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic analysis of myeloproliferative neoplasms in chronic and acute phases.
    Courtier F; Carbuccia N; Garnier S; Guille A; Adélaïde J; Cervera N; Gelsi-Boyer V; Mozziconacci MJ; Rey J; Vey N; Chaffanet M; Birnbaum D; Murati A
    Haematologica; 2017 Jan; 102(1):e11-e14. PubMed ID: 27742771
    [No Abstract]   [Full Text] [Related]  

  • 18. Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis.
    Merlinsky TR; Levine RL; Pronier E
    Clin Cancer Res; 2019 May; 25(10):2956-2962. PubMed ID: 30655313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm.
    Rampal R; Mascarenhas J
    Curr Opin Hematol; 2014 Mar; 21(2):65-71. PubMed ID: 24366192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms.
    Mondello P; Di Mirto C; Cuzzocrea S; Arrigo C; Mian M; Pitini V
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e489-e495. PubMed ID: 31231012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.